SalioGen Therapeutics (Series B)
Funding Details
Awarder
Inbox
Date Award
January 5, 2022
Vertical
Genetic Medicine
Funding URL
View Funding Page
Funding Amount
$115,000,000
Company Info
Founders
Ray Tabibiazar
Market
Inherited Diseases
Location
Cambridge, MA, USA
Coinvestors
Cystic Fibrosis Foundation, D1 Capital Partners, EPIQ Capital Group, Fidelity Management & Research Company, GordonMD Global Investments, PBM Capital Group, RD Fund, Symbiosis, T. Rowe Price Associates
Company Description

SalioGen Therapeutics has launched Gene Coding, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration Technology (EDITTM) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines.

Links
Website
Back to HomeBack to Genetic Medicine DealsView Funding Announcement